Renn Fund Inc (RCG) formed multiple top with $1.46 target or 6.00% above today’s $1.38 share price. Renn Fund Inc (RCG) has $6.35M valuation. The stock increased 2.22% or $0.03 on April 24, reaching $1.38. About shares traded. Renn Fund Inc (NYSEMKT:RCG) has risen 9.52% since September 16, 2016 and is uptrending. It has underperformed by 1.46% the S&P500.
Among 19 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 12 have Buy rating, 1 Sell and 6 Hold. Therefore 63% are positive. AstraZeneca plc (ADR) had 24 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Buy” rating given on Friday, February 26 by Cantor Fitzgerald. The firm earned “Buy” rating on Friday, September 18 by Bryan Garnier & Cie. The rating was downgraded by BNP Paribas to “Neutral” on Wednesday, September 14. On Monday, September 14 the stock rating was upgraded by Deutsche Bank to “Buy”. HSBC upgraded the stock to “Buy” rating in Wednesday, September 2 report. As per Tuesday, October 20, the company rating was downgraded by Credit Suisse. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Equal-Weight” rating by Barclays Capital on Tuesday, January 19. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Hold” rating by Jefferies on Tuesday, March 15. The rating was upgraded by S&P Research to “Buy” on Friday, July 31. The firm earned “Overweight” rating on Tuesday, December 1 by Morgan Stanley. See AstraZeneca plc (ADR) (NYSE:AZN) latest ratings:
10/04/2017 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
05/04/2017 Broker: UBS Old Rating: Buy New Rating: Neutral Downgrade
09/12/2016 Broker: Leerink Swann Old Rating: Mkt Perform New Rating: Outperform Upgrade
25/11/2016 Broker: Liberum Capital Old Rating: Hold New Rating: Buy Upgrade
The stock increased 1.61% or $0.48 during the last trading session, reaching $30.24. About 13,900 shares traded. AstraZeneca plc (ADR) (NYSE:AZN) has declined 10.59% since September 16, 2016 and is downtrending. It has underperformed by 21.57% the S&P500.
AstraZeneca PLC is a biopharmaceutical company. The company has market cap of $74.86 billion. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 21.88 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
